期刊
FRONTIERS IN PHARMACOLOGY
卷 9, 期 -, 页码 -出版社
FRONTIERS MEDIA SA
DOI: 10.3389/fphar.2018.00700
关键词
specnuezhenide; osteoarthritis; chondrocyte; NF-kappa B; wnt/beta-catenin
资金
- National Natural Science Foundation of China (Hangzhou, Zhejiang, China) [81572173, 81371996, 81401824]
- Chinese Medicine Research Program of Zhejiang Province, China [2015ZB028]
- Natural Science Foundation of Zhejiang Province [LQ18H060001]
As a chronic disease, osteoarthritis (OA) leads to the degradation of both cartilage and subchondral bone, its development being mediated by proinflammatory cytokines like interleukin-1 beta. In the present study, the anti-inflammatory effect of specnuezhenide (SPN) in OA and its underlying mechanism were studied in vitro and in vivo. The results showed that SPN decreases the expression of cartilage matrix-degrading enzymes and the activation of NF-kappa B and wnt/beta-catenin signaling, and increases chondrocyte-specific gene expression in IL-1 beta-induced inflammation in chondrocytes. Furthermore, SPN treatment prevents the degeneration of both cartilage and subchondral bone in a rat model of OA. To the best of our knowledge, this study is the first to report that SPN decreases interleukin-1 beta-induced inflammation in rat chondrocytes by inhibiting the activation of the NF-kappa B and wnt/beta-catenin pathways, and, thus, has therapeutic potential in the treatment of OA.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据